Recent Advances in Peptide Therapeutics

USD 250.00

* Required Fields

USD 250.00


Be the first to review this product

This edition of the Genetic Technology TOE depicts trends across peptide therapeutics. The study covers a variety of disease indications in which peptide therapeutics are being used. A summary of interventional, industry-funded clinical studies using peptide therapeutics for leukemia is also presented.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative

Table of Contents

Recent Advances in Peptide TherapeuticsInnovations in Peptide TherapeuticsStapled Peptides for Advanced Cancer ManagementNovel Therapeutic for Paroxysmal Nocturnal Hemoglobinuria Glucagon Analog for Treating Hypoglycemia in Type 1 DiabeticsSynthetic Surfactant Technology for Management of Respiratory Distress Syndrome in Premature InfantsClinical Trial Analysis and Industry InteractionsClinical Trial AnalysisIndustry Interactions

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.